Abbvie M21-446
Brief description of study
Study M21-446 is a Phase 2a, multicenter, open label proof of concept study to investigate the efficacy and safety of ABBV-668 in subjects with moderate to severe UC. The study contains a 30-day screening period, 16-week treatment period, and a 30-day follow up period from the last dose of study drug.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
